TABLE 1.
Baseline characteristics of the patients enrolled in the study.
| Characteristics | Median [25th – 75th percentile] or number (%) | ||
|---|---|---|---|
| 1st line (n = 10) | 2nd line (n = 36) | ≥3rd line (n = 17) | |
| Sex | |||
| Female | 8 (80.0) | 22 (61.1) | 13 (76.5) |
| Male | 2 (20.0) | 14 (38.9) | 4 (23.5) |
| Age (years) | 63.5 [56.0–71.5] | 70.5 [61.0–73.0] | 66.0 [60.0–72.0] |
| BMI (kg/m 2 ) | 22.5 [21.2–25.2] | 20.8 [19.3–23.8] | 21.73 [19.5–23.8] |
| ECOG PS | |||
| 0 | 6 (60.0) | 10 (27.8) | 6 (35.3) |
| 1 | 4 (40.0) | 16 (44.4) | 10 (58.8) |
| 2 | 0 (0) | 9 (25.0) | 1 (5.9) |
| 3 | 0 (0) | 1 (2.8) | 0 (0) |
| Smoking status | |||
| Never | 9 (90.0) | 28 (77.8) | 14 (82.3) |
| Former | 1 (10.0) | 6 (16.7) | 1 (5.9) |
| Current | 0 (0) | 0 (0) | 1 (5.9) |
| Passive | 0 (0) | 2 (5.5) | 1 (5.9) |
| Staging | |||
| IIIA | 0 (0) | 1 (2.8) | 0 (0) |
| IV | 10 (100.0) | 35 (97.2) | 17 (100) |
| Cerebral metastasis | 2 (20.0) | 4 (11.1) | 7 (41.2) |
| Type of EGFR mutation | |||
| Exon 18 G719x | 0 (0) | 1 (2.8) | 0 (0) |
| Exon 19 deletion | 6 (60.0) | 22 (61.1) | 14 (82.4) |
| Exon 20 insertion | 0 (0) | 1 (2.8) | 0 (0) |
| Exon 21 L858R | 4 (40.0) | 12 (33.3) | 3 (17.6) |
| Exon 20 T790M | 1 (10.0) a | 29 (80.6) b | 16 (94.1) b |
| Dose adjustment | |||
| Dose holding | 1 (10.0) | 3 (8.3) | 3 (17.6) |
| Dose reduction | 3 (30.0) | 9 (25.0) | 5 (29.4) |
BMI, body mass index; ECOG PS, eastern cooperative oncology group performance status; EGFR, epidermal growth factor receptor.
a
De novo EGFR, Exon 20 T790M mutation.
b
Acquired EGFR, Exon 20 T790M mutation.